Evidence map›Paper›PMID 19156230›Full record

ArticleTexas Heart Institute journal2008

Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study.

Vijay Nambi, Alanna C Morrison, Ron C Hoogeveen, Josef Coresh, Shawn Miles, Charles Etta Rhodes, A Richey Sharrett, B Eric Boerwinkle, Christie M Ballantyne

Open access · greenAbstract read
In one paragraph

Article in Texas Heart Institute journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Vijay NambiSection of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
Alanna C Morrison
Ron C Hoogeveen
Josef Coresh
Shawn Miles
Charles Etta Rhodes
A Richey Sharrett
B Eric Boerwinkle
Christie M Ballantyne
Baylor College of Medicine · USJohns Hopkins University · USThe University of Texas Health Science Center at Houston · US

Funding

COMMUNITY AND COHORT SURVEILLANCE PROGRAMS-N01HC55015N01HC055015 · HC · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI CHAMBLESS, LLOYD E · 1985 to 2006
$1.1M
COMMUNITY AND COHORT SURVEILLANCE PROGRAMN01HC055016 · HC · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE M · 1985 to 2000
$785k
CENTRAL HEMOSTATIS LABORATORY FOR CCSPN01HC055022 · HC · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI WU, KENNETH K · 1985 to 2000
$264k
CCSP--FIELD CENTER AND ULTRASOUND READING CENTERN01HC055018 · HC · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI HEISS, GERARDO · 1985 to 2000
$104k
SKELETAL MUSCLE ENERGY CONVERTOR FOR CARDIAC ASSISTANCER41HL055018 · NHLBI · THORATEC LABORATORIES CORPORATION · PI FARRAR, DAVID J · 1995 to 1995
–
SKELETAL MUSCLE ENGERGY CONVERTOR FOR CARDIAC ASSISTANCER42HL055018 · NHLBI · THORATEC LABORATORIES CORPORATION · PI FARRAR, DAVID J · 1998 to 1999
–
NHLBI NIH HHS N01 HC055015NHLBI NIH HHS N01 HC055016NHLBI NIH HHS N01 HC055018NHLBI NIH HHS N01 HC055022NHLBI NIH HHS N01-HC-55015NHLBI NIH HHS N01-HC-55016NHLBI NIH HHS N01-HC-55018NHLBI NIH HHS N01-HC-55022
6 · The paper itself

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) are thought to be associated with coronary artery disease. The association of these markers with incident coronary artery disease has not been well described. Using a case-cohort design, we selected 216 individuals who had incident coronary artery disease (case group) and 225 individuals from a cohort random sample (comparison group) from participants enrolled in the Atherosclerosis Risk in Communities study. We measured plasma levels of MMP-1 and TIMP-1, traditional risk factors, and other markers of inflammation. We found no significant difference in TIMP-1 levels between the case group (827.8 +/- 23.8 ng/mL) and the comparison group (819.31 +/- 16.1 ng/mL) (P=0.77), and no significant difference in the frequency of MMP-1 levels that were dichotomized at the minimum detectable value of 1.7 ng/mL (P=0.49). In models adjusted for age, sex, race, body mass index, hypertension, diabetes, total cholesterol, high-density lipoprotein cholesterol, triglycerides, fibrinogen, von Willebrand factor, and white blood cell count, the hazard-rate ratio for incident coronary artery disease was 1.14 (95% confidence interval, 0.63-2.04; P=0.67) for individuals whose TIMP-1 levels were above, versus at or below the mean, and 1.17 (95% confidence interval, 0.63-2.19; P=0.62) for individuals whose MMP-1 levels were above 1.7 ng/mL. We conclude that TIMP-1 and MMP-1 levels in plasma were not predictive of incident coronary artery disease in a case-cohort random sample of the Atherosclerosis Risk in Communities study, a population study of asymptomatic middle-aged adults who had no prevalent atherosclerosis upon enrollment.

Indexed as

BiomarkersCase-Control StudiesConfidence IntervalsCoronary Artery DiseaseFemaleHumansIncidenceMaleMatrix Metalloproteinase 1Middle AgedOdds RatioRisk FactorsTexasTissue Inhibitor of Metalloproteinase-1BiomarkersMatrix Metalloproteinase 1Tissue Inhibitor of Metalloproteinase-1Biological markers/analysiscoronary artery disease/enzymology/physiopathologymatrix metalloproteinase-1risk factorstissue inhibitor of metalloproteinase-1

Identifiers

PMID19156230
PMCPMC2607088
OpenAlexW206805405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.